It will be the first indigenous vaccine to target Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. Read on to find out more.
In a major step forward for indigenous healthcare innovation, the Indian Council of Medical Research (ICMR) has announced the development of a groundbreaking malaria vaccine candidate named AdFalciVax. This novel vaccine is being created through a collaborative effort between ICMR’s Regional Medical Research Centre in Bhubaneswar (RMRCBB), the National Institute of Malaria Research (NIMR), and the Department of Biotechnology’s National Institute of Immunology (DBT-NII). The initiative aligns with the Government of India’s ‘Make in India’ vision and aims to address one of the world’s most persistent and deadly diseases — malaria.
AdFalciVax is not just another malaria vaccine. It represents India’s first indigenous recombinant chimeric malaria vaccine specifically designed to target two key stages of Plasmodium falciparum, the most dangerous and deadly species of malaria-causing parasites. Most existing malaria vaccines are designed to act against a single life-cycle stage of the parasite, but the AdFalciVax vaccine is being developed to make it a multi-stage solution, which gives it the potential to protect individuals from infection and simultaneously reduce the chances of community-level transmission by the mosquito vector.
The vaccine has so far shown promising pre-clinical results, suggesting multiple advantages over the current malaria vaccines.
- Firstly, by targeting two critical stages of the parasite’s lifecycle, AdFalciVax may offer a broader and more effective protection, reducing the chances of immune evasion. This multistage targeting could lead to enhanced immunity, which is a crucial factor in sustained malaria prevention, particularly in high-transmission regions.
- Secondly, the vaccine has demonstrated superior thermal stability, with evidence indicating that it remains functional for over nine months at room temperature. This feature is particularly valuable in remote and tropical regions where cold temperatures pose a major challenge.
AdFalciVax is as per the initial estimations being regarded as one of the most scientifically advanced malaria vaccine candidates in global development, given its make-design and focus on interrupting both infection and transmission. As malaria remains a significant public health issue in many parts of India and sub-Saharan Africa, the success of this vaccine could have far-reaching implications.
The ICMR has stated that it will make the technology behind AdFalciVax available to eligible organisations and vaccine manufacturers through non-exclusive licensing agreements. This strategy is intended to accelerate the development, large-scale manufacturing, and eventual commercialization of the vaccine while ensuring equitable access. All licensing and collaborations will follow ICMR’s established Intellectual Property (IP) Policy, ensuring scientific transparency and fair use. India’s medical field has been creating waves in the global healthcare circuit and such discoveries only fortify the presence, intelligence and capability researchers in the country possess.
It is important to note that AdFalciVax is still in the early stages of research and development and is not yet approved for clinical use. However, its emergence marks a significant milestone in India’s fight against malaria and showcases the country’s growing scientific capabilities in vaccine development.
The doctors in this regard have been quite optimistic about the advancements being carried out, and the results will prove to have high efficacy for the patients to better their pain management. If successful, AdFalciVax could become a key tool in global malaria eradication efforts, especially in endemic regions, and reinforce India’s position as a leader in affordable and innovative public health solutions.
Helene Elliott is the senior reporter for News Raise. She covers Science news. She also has a keen interest in photojournalism. Helene holds a nomination for the prestigious Red Smith Award. She is married to author Dennis D’Agostino, a former publicist with the New York Mets.
